Related Experiment Video
Updated: Apr 30, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Next-generation sequencing: a change of paradigm in molecular diagnostic validation
Manuel Salto-Tellez1, David Gonzalez de Castro
1Northern Ireland Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology, Queen's University Belfast, UK.
Abstract:
Next-generation sequencing (NGS) is beginning to show its full potential for diagnostic and therapeutic applications. In particular, it is enunciating its capacity to contribute to a molecular taxonomy of cancer, to be used as a standard approach for diagnostic mutation detection, and to open new treatment options that are not exclusively organ-specific. If this is the case, how much validation is necessary and what should be the validation strategy, when bringing NGS into the diagnostic/clinical practice? This validation strategy should address key issues such as: what is the overall extent of the validation? Should essential indicators of test performance such as sensitivity of specificity be calculated for every target or sample type? Should bioinformatic interpretation approaches be validated with the same rigour? What is a competitive clinical turnaround time for a NGS-based test, and when does it become a cost-effective testing proposition? While we address these and other related topics in this commentary, we also suggest that a single set of international guidelines for the validation and use of NGS technology in routine diagnostics may allow us all to make a much more effective use of resources.
Insights
Next-generation sequencing (NGS) offers significant diagnostic and therapeutic potential in oncology. Establishing clear validation strategies and international guidelines is crucial for integrating NGS into routine clinical practice and maximizing resource efficiency.
Area of Science:
- Genomic Medicine
- Molecular Diagnostics
- Clinical Bioinformatics
Background:
- Next-generation sequencing (NGS) is increasingly recognized for its diagnostic and therapeutic applications in cancer.
- NGS enables molecular cancer taxonomy, mutation detection, and personalized treatment strategies beyond organ specificity.
Purpose of the Study:
- To discuss the necessary validation strategies for implementing NGS in clinical diagnostics.
- To address key considerations for NGS test validation, including scope, performance metrics, bioinformatic interpretation, turnaround time, and cost-effectiveness.
Main Methods:
- This commentary reviews current challenges and proposes a framework for NGS validation.
- It addresses critical aspects such as defining validation extent, calculating performance indicators (sensitivity, specificity), validating bioinformatic pipelines, and assessing turnaround times and cost-effectiveness.
Main Results:
- The commentary highlights the need for rigorous validation of NGS assays and bioinformatic analyses before clinical adoption.
- It emphasizes that a standardized validation approach is essential for reliable diagnostic and therapeutic applications.
Conclusions:
- A unified set of international guidelines for NGS validation and clinical use is proposed.
- Implementing such guidelines will enhance resource utilization and facilitate the effective integration of NGS into routine diagnostics.
More Related Videos
Related Concept Videos
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Modern Molecular Taxonomy
Sanger Sequencing
Maxam-Gilbert Sequencing
Challenges of the Maxam-Gilbert Method
The...

